NCT07150767View on ClinicalTrials.gov

A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 26, 2025

Primary Completion Date

March 26, 2027

Study Completion Date

March 26, 2027

Conditions
Locally Advanced Breast Cancer (LABC)
Interventions
BIOLOGICAL

BioTTT001 injection

BioTTT001 is administered as a multiple Intratumoral injection. The dose groups to be infusion were 5.0×10\^10 viral particle (VP) ,2.0×10\^11 VP and 5×10\^11 VP based on the 3+3 dose escalation principle.

Trial Locations (1)

250022

The Second People's Hospital of Shandong Province, Jinan

All Listed Sponsors
lead

Beijing Bio-Targeting Therapeutics Technology Co., Ltd

INDUSTRY